NORTH-AMERICAN (UNITED-STATES AND CANADA) COMPARATIVE SUSCEPTIBILITY OF 2 FLUOROQUINOLONES - OFLOXACIN AND CIPROFLOXACIN - A 53-MEDICAL-CENTER SAMPLE OF SPECTRA OF ACTIVITY
Rn. Jones et al., NORTH-AMERICAN (UNITED-STATES AND CANADA) COMPARATIVE SUSCEPTIBILITY OF 2 FLUOROQUINOLONES - OFLOXACIN AND CIPROFLOXACIN - A 53-MEDICAL-CENTER SAMPLE OF SPECTRA OF ACTIVITY, Diagnostic microbiology and infectious disease, 18(1), 1994, pp. 49-56
Ofloxacin, a newer broad-spectrum fluoroquinolone, was evaluated again
st > 12,000 clinical isolates in a multicenter surveillance trial in t
he United States and Canada using the standardized disk diffusion meth
od. A total of 53 geographically diverse clinical microbiology laborat
ories contributed zone diameter results for ofloxacin, ciprofloxacin,
and norfloxacin for urinary tract infection (UTI) isolates; and ofloxa
cin and ciprofloxacin for respiratory tract infection (RTI) isolates,
skin and soft tissue infection (SSTI) isolates, and genital tract path
ogen isolates. In both the USA and Canada, ofloxacin was shown to have
the wide spectrum of activity as follows: RTI isolates, ofloxacin (92
.2%-93.8% susceptible), ciprofloxacin (89.5%-90.4%); SSTI isolates, of
loxacin (87.1%-93.6%) > ciprofloxacin (78.8%-90.4%); UTI isolates, ofl
oxacin (91.6%-92.5%) > norfloxacin (87.3%-91.7%) > ciprofloxacin (86.4
%-89.7%); and genital tract isolates, ofloxacin (94.0%) > ciprofloxaci
n (85.4%) (Canada only). US strains resistant to ofloxacin were confir
med by reference laboratory tests. Confirmed ofloxacin resistance, oth
er than among staphylococci or nonenteric bacilli, was rare. The speci
es most often found to be resistant to both ofloxacin and ciprofloxaci
n were methicillin-resistant staphylococci, Acinetobacter spp., and En
terococcus spp. From these contributing US and Canadian laboratory stu
dies, ofloxacin appears to have a balanced spectrum of potential clini
cal use (91.8% susceptible aerobic isolates), particularly against Gra
m-positive pathogens and some species resistant to ciprofloxacin. The
combined overall isolate (12,241 isolates) rates of susceptibility for
ciprofloxacin (four infection sites) and norfloxacin (UTI only) were
87.3% and 88.8%, respectively. Monitoring for increasing fluoroquinolo
ne resistance should be considered, however, as greater use of drugs i
n this class develops.